HorizonTech
HorizonTech Raises $350M Series E to Transform Biotech
Quick Facts
HorizonTech Raises $350M Series E in Latest Funding Round
HorizonTech has successfully closed a $350M Series E funding round, marking a significant milestone in the company's growth trajectory. The round was led by 500 Startups, with participation from Khosla Ventures.
Company Overview
Founded in 2023 and headquartered in Portland, OR, HorizonTech has established itself in the Biotech space. Leading AI-powered analytics platform transforming data into actionable business insights
With a current valuation of $5B, the company has demonstrated strong market traction and investor confidence.
Investment Details
- Amount Raised: $350M Series E
- Valuation: $5B
- Lead Investor: 500 Startups
Future Outlook
As HorizonTech moves forward with its expanded funding, the company is well-positioned to capitalize on market opportunities and drive innovation in the biotech space.
Key Investors
About the Author
Related Company Reports
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza